Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.43 |
| ▸ | PDE4A | P27815 | 6/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29830733 | 0.89 | PDE4D (0.45) | NAAAPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL29387041 | 0.86 | NAAA (0.73) | NAAALMNA | |
| SCHEMBL19681634 | 0.86 | NAAA (0.73) | NAAALMNA | |
| SCHEMBL8690677 | 0.86 | — | — | |
| SCHEMBL8394206 | 0.84 | NAAA (0.42) | NAAAPDE4DPDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL32662212 | 0.82 | NAAA (0.41) | NAAAPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2433610 | 0.82 | NAAA (0.67) | NAAAALDH1A1SMN1; SMN2EPHX1HTT | |
| SCHEMBL1695592 | 0.82 | NAAA (0.72) | NAAAALDH1A1SMN1; SMN2EPHX1HTT | |
| SCHEMBL7815359 | 0.81 | NAAA (0.51) | NAAAALDH1A1SMN1; SMN2EPHX1HTT | |
| SCHEMBL9134369 | 0.80 | NAAA (0.73) | NAAAALDH1A1SMN1; SMN2EPHX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308558-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-24 | — | — | EP | disclosed |
| CN-109195959-B | Tetrahydropyranyl lower alkyl esters and preparation using ketene compounds | 巴斯夫欧洲公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-3464258-A1 | TETRAHYDROPYRANYL LOWER ALKYL ESTERS AND THE PRODUCTION OF SAME USING A KETENE COMPOUND | BASF SE (DE) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017207539-A1 | TETRAHYDROPYRANYL LOWER ALKYL ESTERS AND THE PRODUCTION OF SAME USING A KETENE COMPOUND | BASF SE (DE) | 2017-12-07 | — | — | WO | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2125792-B1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-4849436-A | TREATMENT OF CARDIOVASCULAR DISORDERS | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0259462-A1 | 1,4-DIHYDROPYRIDINES | Whitby Research Incorporated (US) | 1988-03-16 | — | — | EP | disclosed |
| WO-1987005512-A1 | 1,4-DIHYDROPYRIDINES | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1987-09-24 | — | — | WO | disclosed |
| EP-0099692-B1 | NEW FURANONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-18 | — | — | EP | disclosed |
| US-4585789-A | ALDOSE REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283438-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | NAAA 1190/4885PDE4D 928/4885PDE4A 495/4885 |
| US-20090131458-A1 | Compounds | LTC4S, LTB4R2, LTB4R | NAAA 1190/4885PDE4D 928/4885PDE4A 495/4885 |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | LTC4S, STING1, LTB4R2 | NAAA 2007/4885PDE4D 1206/4885PDE4A 488/4885 |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | NAAA 441/4885PDE4D 1886/4885PDE4A 1314/4885 |
| US-20110269781-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | NAAA 1190/4885PDE4D 928/4885PDE4A 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.